𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Molecular-based strategies for assessment of CMV infection and disease in immunosuppressed transplant recipients

✍ Scribed by A. Kulkarni; D. Westmoreland; J. D. Fox

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
113 KB
Volume
7
Category
Article
ISSN
1198-743X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Question of using valganciclovir for cyt
Question of using valganciclovir for cytomegalovirus (CMV) infection prophylaxis in post–liver transplant recipients
✍ Ashok Jain; Ravi Mohanka; Mark Orloff; Peter Abt; Charlotte Ryan; Adel Bozorgzad 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 46 KB

We read the article by Park et al. with great interest. 1 The authors retrospectively studied the efficacy of low-dose oral valganciclovir (n ϭ 49) compared with the standard dose of ganciclovir (n ϭ 60) for the prevention of cytomegalovirus (CMV) disease in adult liver transplant recipients. The au

Kinetics of cytomegalovirus (CMV) pp65 a
Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFNγ CD8+ and CD4+ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: Potential implications for the management of active CMV infection
✍ Nuria Tormo; Carlos Solano; Isabel Benet; José Nieto; Rafael de la Cámara; Ana G 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB

## Abstract The dynamics of CMV pp65 and IE‐1‐specific IFNγ‐producing CD8^+^ (IFNγ CD8^+^) and CD4^+^ (IFNγ CD4^+^) T cells and CMV DNAemia were assessed in 19 pre‐emptively treated episodes of active CMV infection. Peripheral counts of IFNγ CD8^+^ and IFNγ CD4^+^ T cells inversely correlated with

Clinically-based determination of safe D
Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients
✍ Daniele Lilleri; Fausto Baldanti; Marta Gatti; Francesca Rovida; Luca Dossena; S 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

## Abstract Transplantation Centers using human cytomegalovirus (HCMV) antigenemia‐based preemptive therapy will need to replace in the near future the antigenemia assay with a more standardized and automatable assay, such as a molecular assay quantifying HCMV DNA in blood (DNAemia). Thus, in view

Population-based study of the pattern of
Population-based study of the pattern of molecular markers of minimal residual disease in childhood and adult acute lymphoblastic leukemia: An assessment of the practical difficulty of representative sampling for trial purposes
✍ Middleton, P.G.; Norden, J.; Levett, D.; Levasseur, M.; Miller, S.; Irving, J.A. 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 2 views

Background. The prevalence, in unselected patients with acute lymphoblastic leukaemia (ALL), of clonal rearrangements suitable for minimal residual disease (MRD) studies has not been formally investigated. Procedure. This was a prospective, demographic study of the frequency of molecular markers of